Immune reconstitution in HIV infection and its relationship to cancer

Hematology/Oncology Clinics of North America

Volumn 17, Issue 3, 2003, Pages 703-716

  Robertson, Paul ^a   Scadden, David T ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER RISK; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOREGULATION; INFECTION CONTROL; LYMPHOCYTOPENIA; PERSISTENT VIRUS INFECTION; PRIORITY JOURNAL; REVIEW; VIRUS REPLICATION;

EID: 0038387639     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8588(03)00047-9     Document Type: Review

References (105)

1. Murray CJ, Lopez AD, editors. The global burden of disease and injury series, volume 1: a comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020. Cambridge (MA): Published by the Harvard School of Public Health on behalf of the World Health Organization and the World Bank, Harvard University Press; 1996.
2. + T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 1999;5:512-7.
3. Pallela FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338:853-60.
4. Rickinson A, Moss D. Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection. Annu Rev Immunol 1997; 152:405-31.
5. Schmitz JE, Kuroda MJ, Santra S, et al. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science 1999;283:857-60.
6. Borrow P, Lewick H, Hahn BH, et al. Virus specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol 1994;68:6103-10.
7. Rosenberg ES, Billingsley JM, Caliendo AM, et al. Vigorous HIV-1 specific CD4+ T cell responses associated with control of viremia. Science 1997;278:1447-50.
8. Douek DC, Brenchley JM, Betts MR, et al. HIV preferentially infects HIV-specific CD4+ T cells. Nature 2002;417:95-8.
9. Betts MR, Ambrozak DR, Douek DC, et al. Analysis of total human immunodeficiency virus (HIV)-specific CD4(+) and CD8(+) T-cell responses: relationship to viral load in untreated HIV infection. J Virol 2001;75:11983-91.
10. Spits H. Development of αβ T cells in the human thymus. Nat Immunol Rev 2002;2:760-72.
11. Sempowski GD, Haynes BF. Immune reconstitution in patients with HIV infection. Annu Rev Med 2002;53:269-84.
12. Kong F, Chen CH, Cooper MD. Thymic function can be accurately monitored by the level of recent T-cell emigrants in the circulation. Immunity 1998;8:97-104.
13. Douek DC, McFarland RD, Keiser PH, et al. Changes in thymic function with age and during treatment of HIV infection. Nature 1998;396:690-5.
14. Hazenberg MD, Otto SA, Cohen JW, et al. Increased cell division but not thymic dysfunction rapidly affects the T cell receptor excision circle content of the native cell population in HIV-1 infection. Nat Med 2000;6:1036-42.
15. Ye P, Kirschner DE. Reevaluation of T cell receptor circles as a measure of recent thymic emigrants. J Immunol 2002;169:4968-79.
16. Hazenberg MD, Otto SA, de Pauw ES, et al. T cell receptor excision circle and T cell dynamics after allogenic stem cell transplantation are related to clinical events. Blood 2002;99:3449-53.
17. Arstila TP, Casrouge A, Baron V, et al. A direct estimate of the human αβ T cell receptor diversity. Science 1999;286:958-61.
18. Garderet L, Dulphy N, Douay C, et al. The umbilical cord blood αβ T cell repertoire: characteristics of a polyclonal and naïve but completely formed repertoire. Blood 1998;91:340-6.
19. Gorski J, Yassai M, Zhu X, et al. Circulating T cell repertoire complexity in normal individuals and bone marrow recipients analyzed by CDR3 size spectratyping. Correlation with immune status. J Immunol 1994;152:5109-19.
20. Bomberger C, Singh-Jairam M, Rodey G, et al. Lymphoid reconstitution after autologous PBSC transplantation with FACS-sorted CD34 + hematopoietic progenitors. Blood 1998;91: 2588-600.
21. Raaphorst FM, Schelonka RL, Rusnak J, et al. TCRBV CDR3 diversity of CD4+ and CD8+ T-lymphocytes in HIV-infected individuals. Hum Immunol 2002;63:51-60.
22. Ho DD, Neumann AU, Perelson AS, et al. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995;373:123-6.
23. Pantaleo G, Graziosi C, Fauci AS. New concepts in the immunopathogenesis of human immunodeficiency virus infection. N Engl J Med 1993;328:327-35.
24. Phenix B, Badley AD. Influence of mitochondrial control of apoptosis on the pathogenesis, complications and treatment on HIV infection. Biochimie 2002;84:251-64.
25. Hockett R, Kilby J, Cerdeyn C, et al. Constant mean copy number per infected cell in tissues regardless of high, low or undetectable plasma HIV RNA. J Exp Med 1999;189:1545-54.
26. Koka PS, Jamieson BD, Brooks DG, Zack JA. Human immunodeficiency virus type 1 induced hematopoietic inhibition is independent of productive infection of progenitor cells in vivo. J Virol 1999;73:9089-97.
27. Shen H, Cheng T, Preffer FI, et al. Intrinsic human immunodeficiency virus type 1 resistance of hematopoietic stem cells despite co-receptor expression. J Virol 1999;73:728-37.
28. Bahner I, Kearns K, Coutinho S, et al. Infection of human immunodeficiency virus-1 (HIV-1) is both required and sufficient for HIV-1 inducted hematopoietic suppression in vitro: demonstration by gene modification of primary human stroma. Blood 1997;90:1787-98.
29. Gradstein S, Hahn T, Barak Y, et al. In vitro effects of recombinant TNF-alpha binding protein (rTBP-1) on hematopoiesis of HIV-infected patients. J Acquir Immune Defic Syndr 2001;26: 111-7.
30. Haynes BF, Markert ML, Sempowski GD, et al. The role of the thymus in immune reconstitution in aging, bone marrow transplantation and HIV-1 infection. Annu Rev Immunol 2000; 18:529-60.
31. Stanley SK, McCune JM, Kaneshima H, et al. Human immunodeficiency virus infection of the human thymus and disruption of the thymic microenvironment in the SCID-hu mouse. J Exp Med 1993;178:1151-63.
32. Bonyhadi ML, Rabin L, Salimi S, et al. HIV induces thymus depletion in vivo. Nature 1993; 363:728-32.
33. Jamieson BD, Zack JA. In vivo pathogenesis of a human immunodeficiency virus type 1 reporter virus. J Virol 1998;72:6520-6.
34. Douek DC, Betts MR, Hill BJ, et al. Evidence for increased T cell turnover and decreased thymic output in HIV infection. J Immunol 2001;167:6663-8.
35. Ometto L, De Fomi D, Patiri F, et al. Immune reconstitution in HIV-1 infected children on antiretroviral therapy: role of thymic output and viral fitness. AIDS 2002;16:839-49.
36. Franco JM, Rubio A, Martinez-Moya M, et al. T cell repopulation and thymic volume in HIV-1 infected adult patients after highly active antiretroviral therapy. Blood 2002;99:3702-6.
37. Kolte L, Dreves AM, Ersboll AK, et al. Association between larger thymic size and higher thymic output in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy. J Infect Dis 2002;185:1578-85.
38. Teixeira L, Valdez H, McCune JM, et al. Poor CD4 T cell restoration after suppression of HIV-1 replication may reflect lower thymic function. AIDS 2001;15:1749-56.
39. + T cells in human immunodeficiency virus-infected patients experiencing virologic treatment failure: role of changes in thymic output and T cell death. J Infect Dis 2001;183:1009-16.
40. Stoddart CA, Liegler TJ, Mammano F, et al. Impaired replication of protease inhibitor-resistant HIV-1 in human thymus. Nat Med 2001;7:712-8.
41. Mussini C, Pinti M, Borghi V, et al. Features of CD-4 exploders, HIV positive patients with an optimal immune reconstitution after potent antiretroviral therapy. AIDS 2002;16:1609-16.
42. Haynes BF, Hale LP, Weinhold KJ, et al. Analysis of the adult thymus in reconstitution of T lymphocytes in HIV0-1 infection. J Clin Invest 1999;103:453-60.
43. Sempowski G, Thomasch J, Gooding M, et al. Effect of thymectomy on human peripheral blood T cell pools in myasthenia gravis. J Immunol 2001;166:2808-17.
44. Hellerstein M, Hanley MB, Cesar D, et al. Directly measured kinetics of circulating T lymphocytes in normal and HIV-1 infected humans. Nat Med 1999;5:83-9.
45. Mohri H, Perelson AS, Tung K, et al. Increased turnover of T lymphocytes in HIV-1 infection and its reduction by antiretroviral therapy. J Exp Med 2001;194:1277-87.
46. Fleury S, de Boer RJ, Rizzardi GP, et al. Limited CD4+ T cell renewal in early HIV-1 infection: effect of highly active anti-retroviral therapy. Nat Med 1998;4:794-801.
47. Sachsenberg N, Perelson AS, Yerly S, et al. Turnover of CD4+ and CD8+ lymphocytes in HIV-1 infection as measured by Ki-67 antigen. J Exp Med 1998;187:1295-303.
48. Lempicki RA, Kovacs JA, Baseler MW, et al. Impact of HIV-1 infection and highly active antiretroviral therapy on the kinetics of CD4+ and CD8+ T cell turnover in HIV-infected patients. Proc Natl Acad Sci USA 2000;97:13778-83.
49. McCune JM, Hanley MB, Cesar D, et al. Factors influencing T-cell turnover in HIV-1 sero-positive patients. J Clin Invest 2000;105:R1-8.
50. Kovacs JA, Lempicki RA, Sidorov IA, et al. Identification of dynamically distinct subpopulations of T lymphocytes that are differentially affected by HIV. J Exp Med 2001;194:1731-41.
51. Grossman Z, Meier-Schellersheim M, Sousa AE, et al. CD4 depletion in HIV infection: are we any closer to understanding the cause? Nat Med 2002;8:319-23.
52. Pakker NG, Notermans DW, be Boer RJ, et al. Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: a composite of redistribution and proliferation. Nat Med 1998;4:208-14.
53. Bucy RP, Hockett RD, Derdeyn CA, et al. Initial increase in blood CD4(+) lymphocytes after HIV antiretroviral therapy reflects redistribution from lymphoid tissues. J Clin Invest 1999; 103:1391-8.
54. Roger PM, Breittmayer JP, Durant J, et al. Early CD4(+) T cell recovery in human immunodeficiency virus-infected patients receiving effective therapy is related to a down-regulation of apoptosis and not to proliferation. J Infect Dis 2002;185:463-70.
55. Autran BG, Carcelain TS, Li C, et al. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 1997;277:112-6.
56. Fournier A-M, Baillat V, Alix-Panabieres C, et al. Dynamics of spontaneous HIV-1 specific and non-specific B-cell responses in patients receiving antiretroviral therapy. AIDS 2002;16: 1755-60.
57. Pitcher CJ, Quittner C, Peterson DM, et al. HIV-1 specific CD4 T cells are detectable in most individuals with active HW-1 infection, but decline with prolonged viral suppression. Nat Med 1999;5:518-25.
58. Rosenberg ES, Altfeld M, Poon SH, et al. Immune control of HIV-1 after early treatment of acute infection. Nature 2000;407:523-6.
59. Oxenius A, Price DA, Gunthard HF, et al. Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection. Proc Natl Acad Sci USA 2002;99:13747-52.
60. Martinez-Maza O, Breen EC. B cell activation and lymphoma in patients with HIV. Curr Opin Oncol 2002;14:528-32.
61. Smith KA. To cure chronic HIV infection, a new therapeutic strategy is needed. Curr Opin Immunol 2001;13:617-24.
62. De Milito A, Morch C, Sonnerborg A, Chiodi F. Loss of memory (CD27) B-lymphocytes in HIV-1 infection. AIDS 2001;15:957-64.
63. Evans RH, Scadden DT. Haematological aspects of HIV infection. Baillieres Clin Haematol 2000;13:215-30.
64. Clerici M, Galli M, Bosis S, et al. Immunoendocrinologic abnormalities in human immunodeficiency virus infection. Ann NY Acad Sci 2000;917:956-61.
65. Stone SF, Price P, Tay-Keamey ML, French MA. Cytomegalovirus (CMV) retinitis immune restoration disease occurs during highly active antiretroviral therapy-induced restoration of CMV-specific immune responses within a predominant Th2 cytokine environment. J Infect Dis 2002;185:1813-7.
66. Koval CE, Gigliotti F, Nevins D, Demeter LM. Immune reconstitution syndrome after successful treatment of Pneumocystis carinii pneumonia in a man with human immunodeficiency virus type 1 infection. Clin Infect Dis 2002;35:491-3.
67. Barry SM, Lipman MC, Deery AR, et al. Immune reconstitution pneumonitis following Pneumocystis carinii pneumonia in HIV-infected subjects. HIV Med 2002;3:207-11.
68. Hassell M, French MA. Mycobacterium avium infection and immune restoration disease after highly active antiretroviral therapy in a patient with HIV and normal CD4 counts. Eur J Clin Microbiol Infect Dis 2001;20:889-91.
69. Desimore J, Pomerantz R, Babinchak T. Inflammatory reactions in HIV-1 infected after initiation of highly active antiretroviral therapy. Ann Intern Med 2000;133:447-54.
70. Jubault V, Penfomis A, Schillo F, et al. Sequential occurrence of thyroid autoantibodies and Graves' disease after immune restoration in severely immunocompromised human immunodeficiency virus-1 infected patients. J Clin Endocrinol Metab 2000;85:4254-7.
71. Makela P, Howe L, Glover S, et al. Recurrent Guillain-Barre syndrome as a complication of immune reconstitution in HIV. J Infect 2002;44:47-9.
72. Penn I. Tumors arising in organ transplant recipients. Adv Cancer Res 1978;28:31-61.
73. Stewart T, Tsai SC, Grayson R, et al. Incidence of de novo breast cancer in women chronically immunosuppressed after organ transplantation. Lancet 1995;246:795-8.
74. Gallagher B, Wang Z, Schymura MJ, et al. Cancer incidence in New York State acquired immunodeficiency syndrome patients. Am J Epidemiol 2001;154:544-56.
75. Frisch M, Biggar RJ, Engels EA, Goedert JJ. Association of cancer with AIDS-related immunosuppression in adults. JAMA 2001;285:1736-45.
76. International Collaboration on HIV and Cancer. Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults. J Natl Cancer Inst 2000; 92:1823-30.
77. Chang Y, Cesarman E, Pessin MS, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 1994;266:1865-9.
78. Kedes DH, Operskalski E, Busch M, et al. The sero-epidemiology of human herpes virus 8 (Kaposi's sarcoma associated herpes virus) distribution of infection in KS risk groups and evidence for sexual transmission. Nat Med 1996;2:918-24.
79. Gao SJ, Kingsley L, Li M, et al. KSHV antibodies among Americans, Italians and Ugandans with and without Kaposi's sarcoma. Nat Med 1996;2:925-8.
80. Ariyoshi K, Schim van der Loeff M, Cook P, et al. Kaposi's sarcoma in the Gambia is less frequent in human immunodeficiency type 2 than in human immunodeficiency type 1 despite a high prevalence of human herpes virus 8. J Hum Virol 1998;1:193-9.
81. Hengge UR, Ruzicka T, Tyring SK, et al. Update on Kaposi's sarcoma and other HHV8 associated diseases. Part 2: pathogenesis, Castleman's disease, and pleural effusion lymphoma. Lancet Infect Dis 2002;2:344-52.
82. Coscoy L, Ganem D. Kaposi's sarcoma-associated herpesvirus encodes two proteins that block cell surface display of MHC class 1 chains by enhancing their endocytosis [published correction appears in Proc Natl Acad Sci USA 2001;98:2111.] Proc Natl Acad Sci USA 2000;97: 8051-6.
83. Ishido S, Wang C, Lee BS, et al. Downregulation of major histocompatability complex class 1 molecules by Kaposi's sarcoma-associated herpesvirus K3 and K5 proteins. J Virol 2000;74: 5300-9.
84. Ishido S, Choi JK, Lee BS, et al. Inhibition of natural killer cell-mediated cytotoxicity by Kaposi's sarcoma-associated herpesvirus K5 protein. Immunity 2000;13:365-74.
85. Brander C, Suscovich T, Lee Y, et al. Impaired CTL recognition of cells latently infected with Kaposi's sarcoma associated herpes virus. J Immunol 2000;165:2077-83.
86. Wang QJ, Jenkins FJ, Jacobson LP, et al. CD8+ cytotoxic T lymphocyte responses to lytic proteins of human herpes virus 8 in human immunodeficiency virus type-1 infected and uninfected individuals. J Infect Dis 2000;182:928-32.
87. Wang QJ, Huang XL, Rappocciolo G, et al. Identification of an HLA A* 0201-restricted CD8+ T cell epitope for the glycoprotein B homolog of human herpesvirus 8. Blood 2002;99: 3360-6.
88. Strickler HD, Goedert JJ, Bethke FR, et al. Human herpesvirus 8 cellular responses in homosexual men. J Infect Dis 1999;180:1682-5.
89. Tirelli U, Bernardi D. Impact of HAART on the clinical management of AIDS-related cancers. Eur J Cancer 2001;37:1320-4.
90. Dupin N, Rubin de Cerevens V, Gorin I, et al. The influence of highly active antiretroviral therapy on AIDS-associated Kaposi's sarcoma. Br J Dermatol 1999; 140:875-81.
91. Boshoff C, Weiss R. AIDS-related malignancies. Nat Rev Cancer 2002;2:373-82.
92. Wilkinson J, Cope A, Gill J, et al. Identification of Kaposi's sarcoma-associated herpes virus (HSHV)-specific cytotoxic T-lymphocyte epitopes and evaluation of reconstitution of KSHV-specific responses in human immunodeficiency virus type 1-infected patients receiving highly active antiretroviral therapy. J Virol 2002;76:2634-40.
93. Ensoli B, Gendelman R, Markham P, et al. Synergy between basic fibroblastic growth factor and HIV-1 tat protein in induction of Kaposi's sarcoma. Nature 1994;371:674-80.
94. Sgadari C, Barillari G, Toschi E, et al. HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi's sarcoma. Nat Med 2002;8:225-32.
95. Klein G. Epstein-Barr virus strategy in normal and neoplastic cells. Cell 1994;77:791-3.
96. Grulich AE, Wan X, Law MG, et al. B-cell stimulation and prolonged immune deficiency are risk factors for non-Hodgkin's lymphoma in people with AIDS. AIDS 2000;13:133-40.
97. Van Baarle D, Hovencamp E, Callen MF, et al. Dysfunctional Epstein-Barr virus (EBV)-specific CD8+ T lymphocytes and increased EBV load in HIV-1 infected individuals progressing to AIDS-related non-Hodgkin lymphoma. Blood 2001;98:146-55.
98. Van Baarle D, Kostense S, Hovenkamp E, et al. Lack of Epstein-Barr virus and HIV specific CD27- CD8+ T cells is associated with progression to viral disease in HIV-infection. AIDS 2002;16:2001-11.
99. Eltom MA, Jemal A, Mbulaiteye SM, et al. Trends in Kaposi's sarcoma and non-Hodgkin's lymphoma incidence in the United States from 1973 through 1998. J Natl Cancer Inst 2002; 94:1204-10.
100. Kostense S, Otto SA, Knol GJ, et al. Functional restoration of human immunodeficiency virus and Epstein-Barr virus-specific CD4+ T cells during highly active antiretroviral therapy is associated with an increase in CD4+ T cells. Eur J Immunol 2002;32:1080-9.
101. O'Sullivan CE, Peng R, Cole KS, et al. Epstein-Barr virus and human immunodeficiency virus serological responses and viral burdens in HIV-infected patients treated with HAART. J Med Virol 2002;67:320-6.
102. Luxton JC, Rowe AJ, Cridland JC, et al. Proliferative T cell responses to the human papillomavirus type 16 E7 protein in women with cervical dysplasia and cervical carcinoma and in healthy individuals. J Gen Virol 1996;77:1585-93.
103. Lillo FB, Ferrari D, Veglia F, et al. Human papillomavirus infection and associated cervical disease in human immunodeficiency virus-infected women: effect of highly active antiretroviral therapy. J Infect Dis 2001;184:547-51.
104. Palefsky JM, Holly EA, Ralston ML, et al. Effect of highly active antiretroviral therapy on the natural history of anal squamous intraepithelial lesions and anal human papillomavirus infection. J Acquir Immune Defic Syndr 2001;28:422-8.
105. Minkoff H, Ahdieh L, Massad LS, et al. The effect of highly active antiretroviral therapy on cervical cytologic changes associated with oncogenic HPV among HIV-infected women. AIDS 2001;15:2157-64.